274 related articles for article (PubMed ID: 27633825)
21. Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: description of 3 cases and review of the literature.
Mourão AF; Rustin M; Isenberg D
Clin Exp Rheumatol; 2010; 28(3):408-10. PubMed ID: 20576227
[TBL] [Abstract][Full Text] [Related]
22. Drug persistence, effectiveness and safety assessment of anti-TNF therapies in psoriatic arthritis.
Saad AA; Hyrich KL; Ashcroft DM
Expert Opin Drug Saf; 2011 Mar; 10(2):219-26. PubMed ID: 21208138
[TBL] [Abstract][Full Text] [Related]
23. Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs.
Cantini F; Niccoli L; Nannini C; Cassarà E; Pasquetti P; Olivieri I; Salvarani C
J Rheumatol Suppl; 2009 Aug; 83():78-80. PubMed ID: 19661551
[TBL] [Abstract][Full Text] [Related]
24. DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort.
Lindqvist U; Wernroth ML; Husmark T; Larsson P; Geijer M; Teleman A; Theander E; Alenius GM
Clin Exp Rheumatol; 2017; 35(6):936-942. PubMed ID: 28628468
[TBL] [Abstract][Full Text] [Related]
25. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
[TBL] [Abstract][Full Text] [Related]
26. Safety of anti-tumor necrosis factor agents in psoriatic arthritis - an update.
Palazzi C; D'Angelo S; Leccese P; Padula A; Olivieri I
Expert Opin Drug Saf; 2014 Feb; 13(2):191-6. PubMed ID: 24219428
[TBL] [Abstract][Full Text] [Related]
27. Four cases of Japanese patients with psoriatic arthritis in whom effective treatments by anti-tumor necrosis factor-α drugs were evaluated by magnetic resonance imaging together with improvement of skin lesions.
Yonenaga T; Saeki H; Nakagawa H; Fukuchi O; Umezawa Y; Hayashi M; Ito T; Yanaba K; Tojyo S; Fukuda K
J Dermatol; 2015 Jan; 42(1):49-55. PubMed ID: 25425546
[TBL] [Abstract][Full Text] [Related]
28. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
Helliwell PS; Taylor WJ;
J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
[TBL] [Abstract][Full Text] [Related]
29. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
Elyoussfi S; Thomas BJ; Ciurtin C
Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
[TBL] [Abstract][Full Text] [Related]
30. Psoriatic Arthritis Mutilans: Characteristics and Natural Radiographic History.
Jadon DR; Shaddick G; Tillett W; Korendowych E; Robinson G; Waldron N; Cavill C; McHugh NJ
J Rheumatol; 2015 Jul; 42(7):1169-76. PubMed ID: 25979723
[TBL] [Abstract][Full Text] [Related]
31. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
32. Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis.
Atzeni F; Costa L; Caso F; Scarpa R; Sarzi-Puttini P
J Rheumatol Suppl; 2015 Nov; 93():79-81. PubMed ID: 26523064
[TBL] [Abstract][Full Text] [Related]
33. The Role of Tumor Necrosis Factor-α Blockers in Psoriatic Disease. Therapeutic Options in Psoriatic Arthritis.
Addimanda O; Possemato N; Caruso A; Pipitone N; Salvarani C
J Rheumatol Suppl; 2015 Nov; 93():73-8. PubMed ID: 26523063
[TBL] [Abstract][Full Text] [Related]
34. New Approaches in Tumor Necrosis Factor Antagonism for the Treatment of Psoriatic Arthritis: Certolizumab Pegol.
Cauli A; Piga M; Lubrano E; Marchesoni A; Floris A; Mathieu A
J Rheumatol Suppl; 2015 Nov; 93():70-2. PubMed ID: 26523062
[TBL] [Abstract][Full Text] [Related]
35. Long-term costs and outcomes in psoriatic arthritis patients not responding to conventional therapy treated with tumour necrosis factor inhibitors: the extension of the Psoriatic Arthritis Cost Evaluation (PACE) study.
Olivieri I; Cortesi PA; de Portu S; Salvarani C; Cauli A; Lubrano E; Spadaro A; Cantini F; Ciampichini R; Cutro MS; Mathieu A; Matucci-Cerinic M; Punzi L; Scarpa R; Mantovani LG;
Clin Exp Rheumatol; 2016; 34(1):68-75. PubMed ID: 26633622
[TBL] [Abstract][Full Text] [Related]
36. Hypothesis-free analyses from a large psoriatic arthritis cohort support merger to consolidated peripheral arthritis definition without subtyping.
Stekhoven D; Scherer A; Nissen MJ; Grobéty V; Yawalkar N; Villiger PM; Möller B;
Clin Rheumatol; 2017 Sep; 36(9):2035-2043. PubMed ID: 28432523
[TBL] [Abstract][Full Text] [Related]
37. Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.
Chan MJ; Wen YH; Huang YB; Chuang HY; Tain YL; Lily Wang YC; Hsu CN
J Clin Pharm Ther; 2018 Apr; 43(2):256-264. PubMed ID: 29119581
[TBL] [Abstract][Full Text] [Related]
38. Tumor necrosis factor inhibitors continuation rates in patients with psoriatic arthritis: A French retrospective monocentre study.
Rio S; Vincent FB; Michel M; Cesini J; Marcelli C
Joint Bone Spine; 2015 Oct; 82(5):377-8. PubMed ID: 25677408
[No Abstract] [Full Text] [Related]
39. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study.
Ogdie A; Yu Y; Haynes K; Love TJ; Maliha S; Jiang Y; Troxel AB; Hennessy S; Kimmel SE; Margolis DJ; Choi H; Mehta NN; Gelfand JM
Ann Rheum Dis; 2015 Feb; 74(2):326-32. PubMed ID: 25351522
[TBL] [Abstract][Full Text] [Related]
40. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy.
Pomerantz RG; Mody E; Husni ME; Qureshi AA
J Drugs Dermatol; 2009 Apr; 8(4):406-12. PubMed ID: 19363860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
